The Right People, page-4

Genentech is undoubtedly interested in Myc. Most Big Pharma of course are interested in Myc, but Genentech paid out serious money in one of their largest research collaborations to date - the March 2012 collaboration with Constellation.

For an unspecified upfront payment and $95m in research funding over three years, Genentech were interested in progressing the research by Constellation in epigenetics and the development of epigentic regulators. Constellation scientists had demonstrated that transcription of the MYC oncogene can be suppressed using small-molecule inhibitors of the BET family of chromatin adapters.

Three years on and presumably over $100m later, Genentech took a pass on its option to buy out Constellation Pharmaceuticals. One thing for certain, Genentech would like to get a return on Myc.